LSC
IONS icon

Lyon Street Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Lyon Street Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-69,554
Closed -$3.07M – 55
2018
Q1 		$3.07M Buy
+69,554
New +$3.53M 0.99% 33

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Lyon Street Capital's IONS Position: Q2 2018 in Review

Lyon Street Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2018, closing a stake of 69,554 shares — an estimated $3.07M sold.

Lyon Street Capital first reported a position in IONS in Q1 2018 and held it in 1 quarter. The position peaked at $3.07M in Q1 2018. 307 funds tracked by Wall St. Rank hold IONS as of Q2 2018.

  • Lyon Street Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Lyon Street Capital sold 69,554 Ionis Pharmaceuticals shares in Q2 2018, an estimated $3.07M.
  • Lyon Street Capital first reported a position in Ionis Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Lyon Street Capital's Ionis Pharmaceuticals position peaked at $3.07M in Q1 2018.
  • 307 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2018.

Based on Lyon Street Capital's 13F filing for Q2 2018, filed 14 Aug 2018.